Trial Profile
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ningetinib (CT053PTSA) in Patients With Advanced Solid Tumors: A Phase I, Single-arm, Single-center, Open-label, Dose-escalation Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Ningetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors HEC Pharm; Sunshine Lake Pharma
- 30 Sep 2020 Status changed from recruiting to completed.
- 09 Sep 2014 New trial record